 Salvage Therapy
"Salvage Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
| Descriptor ID |
D016879
|
| MeSH Number(s) |
E02.895
|
| Concept/Terms |
Salvage Therapy- Salvage Therapy
- Salvage Treatment
- Salvage Treatments
- Treatment, Salvage
- Treatments, Salvage
- Therapy, Salvage
- Salvage Therapies
- Therapies, Salvage
|
Below are MeSH descriptors whose meaning is more general than "Salvage Therapy".
Below are MeSH descriptors whose meaning is more specific than "Salvage Therapy".
This graph shows the total number of publications written about "Salvage Therapy" by people in this website by year, and whether "Salvage Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 1 | 1 | | 1994 | 1 | 1 | 2 | | 1995 | 0 | 1 | 1 | | 1997 | 1 | 1 | 2 | | 1998 | 0 | 1 | 1 | | 1999 | 2 | 1 | 3 | | 2000 | 2 | 2 | 4 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 2 | 2 | | 2003 | 0 | 2 | 2 | | 2004 | 0 | 1 | 1 | | 2005 | 2 | 0 | 2 | | 2006 | 1 | 1 | 2 | | 2007 | 4 | 0 | 4 | | 2008 | 1 | 1 | 2 | | 2009 | 3 | 4 | 7 | | 2010 | 2 | 4 | 6 | | 2011 | 1 | 1 | 2 | | 2012 | 3 | 0 | 3 | | 2013 | 3 | 0 | 3 | | 2014 | 4 | 1 | 5 | | 2015 | 2 | 4 | 6 | | 2016 | 2 | 2 | 4 | | 2017 | 4 | 6 | 10 | | 2018 | 7 | 3 | 10 | | 2019 | 4 | 3 | 7 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Salvage Therapy" by people in Profiles.
-
Choudhury R, Barrett CD, Moore HB, Moore EE, McIntyre RC, Moore PK, Talmor DS, Nydam TL, Yaffe MB. Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis. World J Emerg Surg. 2020 04 20; 15(1):29.
-
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020 01; 21(1):121-133.
-
Russo S, Anker CJ, Abdel-Wahab M, Azad N, Bianchi N, Das P, Dragovic J, Goodman KA, Jones W, Kennedy T, Kumar R, Lee P, Sharma N, Small W, Suh WW, Jabbour SK. Executive Summary of the American Radium Society Appropriate Use Criteria for Treatment of Anal Cancer. Int J Radiat Oncol Biol Phys. 2019 11 01; 105(3):591-605.
-
Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, Wieder ED, Kolonias D, Rosenberg AE, Kerr DA, Sfakianaki E, Foley M, Merchan JR, Komanduri KV, Trent JC. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol. 2019 06; 20(6):837-848.
-
Stevens B, Winters A, Gutman JA, Fullerton A, Hemenway G, Schatz D, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Drusbosky L, Cogle CR, Hammes A, Abbott D, Jordan CT, Smith C, Pollyea DA. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. Leuk Res. 2019 06; 81:43-49.
-
Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE. Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 05; 25(5):845-854.
-
Marques de Marino P, Malgor RD, Verhoeven EL, Katsargyris A. Rescue of proximal failure of endovascular abdominal aortic aneurysm repair with standard and fenestrated grafts. J Cardiovasc Surg (Torino). 2019 Apr; 60(2):159-166.
-
Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019 01 10; 12(1):6.
-
Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Fayad LE, Khoury JD, Medeiros LJ, Dabaja BS, Nastoupil LJ. Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. Clin Lymphoma Myeloma Leuk. 2019 04; 19(4):244-250.
-
Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with =25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019 01; 107:142-152.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|